Simon D Taylor-Robinson, MD, *Series Editor*

Non-invasive means of measuring hepatic fat content

Sanjeev R Mehta, E Louise Thomas, Jimmy D Bell, Desmond G Johnston, Simon D Taylor-Robinson

Sanjeev R Mehta, Desmond G Johnston, Simon D Taylor-Robinson, Division of Medicine, Imperial College London, St Mary's Campus, Praed Street, London W2 1NY, United Kingdom

E Louise Thomas, Jimmy D Bell, Imaging Sciences Department, Division of Clinical Sciences, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 OHS, United Kingdom

Correspondence to: Dr. Sanjeev R Mehta, Department of Metabolic Medicine, Division of Medicine, Imperial College London, St Mary's Campus, 2nd Floor, Mint Wing, St Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. s.mehta@imperial.ac.uk
Telephone: +44-207-8866120 Fax: +44-207-8861790

Abstract

Hepatic steatosis affects 20% to 30% of the general adult population in the western world. Currently, the technique of choice for determining hepatic fat deposition and the stage of fibrosis is liver biopsy. However, it is an invasive procedure and its use is limited, particularly in children. It may also be subject to sampling error. Non-invasive techniques such as ultrasound, Computerized tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (^{1}H MRS) can detect hepatic steatosis, but currently cannot distinguish between simple steatosis and steatohepatitis, or stage the degree of fibrosis accurately. Ultrasound is widely used to detect hepatic steatosis, but its sensitivity is reduced in the morbidly obese and also in those with small amounts of fatty infiltration. It has been used to grade hepatic fat content, but this is subjective. CT can detect hepatic steatosis, but exposes subjects to ionizing radiation, thus limiting its use in longitudinal studies and in children. Recently, magnetic resonance (MR) techniques using chemical shift imaging have provided a quantitative assessment of the degree of hepatic fatty infiltration, which correlates well with liver biopsy results in the same patients. Similarly, *in vivo* ^{1}H MRS is a fast, safe, non-invasive method for the quantification of intrahepatocellular lipid (IHCL) levels. Both techniques will be useful tools in future longitudinal clinical studies, either in examining the natural history of conditions causing hepatic steatosis (e.g. non-alcoholic fatty liver disease), or in testing new treatments for these conditions.

INTRODUCTION

In humans, adipose tissue is an important "energy bank" in which excess energy is stored and then released to meet the energy needs of the body. In the fed state and during periods of excess calorie intake, the excess energy is stored within adipose tissue as triglycerides. In the fasting state and during starvation, triglycerides within adipose tissue can be rapidly broken down by hormone-sensitive lipase to generate fatty acids. Oxidation of fatty acids releases more energy than that of carbohydrate, protein or triglycerides. Fatty acids are thus the most efficient "fuel" to meet the body's energy needs[1].

In addition to playing an important role in energy homeostasis, adipose tissue is now well recognised as an endocrine organ[2,3]. It is known to produce and secrete a wide variety of bioactive peptides, known as adipokines. These include proteins, such as leptin, adiponectin, resistin, as well as the recently described visfatin and retinol binding protein 4[4-8]. In addition, proinflammatory cytokines, such as tumour necrosis factor alpha and interleukin-6, and acute phase reactants,

such as C-reactive protein are also secreted by the adipocyte. All of these adipokines may act at both a local (paracrine) and systemic (endocrine) level and contribute to the development of obesity-related disorders, such as insulin resistance, Type 2 diabetes and cardiovascular disease[2,3].

Adipose tissue stores may become saturated, either due to failure to develop adequate adipose tissue mass (lipodystrophy), or to expand these stores sufficiently to accommodate increased energy intake. When this occurs, lipid starts to accumulate in non-adipose cells. Ectopic storage of lipids in organs, such as the liver, skeletal muscle and pancreas (the "lean body mass") is thought to play a critical role in the development of insulin resistance and Type 2 diabetes[9]. The accumulation of ectopic fat has been shown to affect both renal and cardiovascular function and may contribute to the development of cardiovascular disease[10].

Evidence to support the hypothesis that ectopic fat accumulation plays a crucial role in insulin resistance comes from the study of subjects with lipodystrophies. These subjects have insufficient adipose tissue mass and hence store excess energy as triglycerides within organs, such as liver and skeletal muscle. As a result, individuals may develop insulin resistance and are at increased risk of developing Type 2 diabetes[11-14].

RELEVANCE OF HEPATIC FAT ACCUMULATION

Fatty infiltration of the liver is not a new phenomenon. However, until the last few decades, fatty liver, particularly that associated with insulin resistance rather than alcohol excess-"non-alcoholic fatty liver disease", was considered to be a relatively benign condition. This notion was challenged when several reports documented the development of liver failure in some patients following jejunal bypass operations for morbid obesity[15-17]. The liver histology in such patients was indistinguishable from that seen in alcoholic steatohepatitis[18]. Similar hepatic lesions were subsequently described in obese patients who had neither abused alcohol nor undergone bariatric surgery[19-21] and in patients with diabetes mellitus[22-24]. In 1980, Ludwig and colleagues introduced the term "non-alcoholic steatohepatitis" (NASH) to describe these histological findings in patients who did not consume alcohol[25]. A variety of other terms have been used to describe this entity with non-alcoholic fatty liver disease now being the preferred term.

Accumulation of fat within the liver is of particular importance in that, over time, it may lead to the development of steatohepatitis and ultimately cirrhosis, end-stage liver failure and hepatocellular carcinoma[26-29].

MECHANISMS OF HEPATIC FAT ACCUMULATION

The mechanisms leading to hepatic fat accumulation remain poorly understood. The liver synthesizes triglycerides from free fatty acids. Free fatty acids are derived from lipolysis of triglycerides within adipose tissue, diet or *de novo* lipogenesis[1]. Once taken up by the liver, free fatty acids can either be oxidised in the mitochondria to form adenosine triphosphate (ATP), or esterified to produce triglycerides for storage, or incorporated into very low density lipoprotein (VLDL) particles. Triglycerides accumulate in the liver when their synthesis exceeds their export *via* VLDL[1,30,31].

The development of non-invasive techniques for assessing hepatic fat content *in vivo* in humans has renewed interest in studying the mechanisms leading to hepatic fat accumulation. Ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (^{1}H MRS) have all played a prominent role in this.

METHODS TO STUDY HEPATIC FAT

Currently, the gold standard for determining hepatic fat severity and morphology is a liver biopsy[31,32]. However, this procedure has several drawbacks, including discomfort, owing to its invasive nature, risk of infection, haematoma formation, or more significant internal bleeding, and biliary leakage. Furthermore, biopsies are subject to sampling error, because less than 1/50 000th of the liver is available for histological analysis.

Non-invasive imaging techniques, such as ultrasound, Computerized tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy can detect fatty infiltration of the liver, but unlike liver biopsy, they are limited in their ability to detect coexisting inflammation or fibrosis.

NON-INVASIVE TECHNIQUES FOR ASSESSING HEPATIC FAT CONTENT

Ultrasound

Hepatic ultrasound is a simple, non-invasive technique, which is widely used in clinical practice to detect fatty infiltration of the liver. As shown in Figure 1, hepatic steatosis causes increased echogenicity on ultrasound, so that liver appears brighter than the cortex of the ipsilateral kidney[33,34].

Diffuse hepatic steatosis and diffuse fibrosis can have similar sonographic appearances and therefore it can sometimes be difficult to distinguish between them. Some groups have used the term "fatty fibrotic pattern" to describe this pattern of increased echogenicity, although the echo shadows tend to be coarser in the presence of pure fibrosis[35,36].

In some cases, fatty infiltration of the liver may be patchy, rather than diffuse, in distribution. The non-uniformity may be so marked that the fat is deposited in one well-circumscribed region (focal fatty infiltration) or, alternatively, discrete areas of liver parenchyma remain uninvolved when the remainder of the liver is diffusely infiltrated with fat (focal fatty sparing). Both

Figure 1 Ultrasound findings in hepatic steatosis. The steatotic liver is hyper-echoic, compared to the cortex of the right kidney. In addition, there is posterior attenuation of the ultrasound beam and reduced definition of the portal vein walls.

Figure 2 CT findings in hepatic steatosis. In this contrast unenhanced scan, the liver appears darker than the spleen and the hepatic vessels appear bright. The increased brightness of the vessels relative to the liver parenchyma may erroneously suggest the use of contrast.

conditions may create diagnostic problems for the radiologist. For example, with focal fatty sparing, if the increased echogenicity of the majority of the liver is not appreciated, then the area of normal hepatic parenchyma may be misinterpreted as a pathological hypoechoic lesion[37]. If, however, the increased echogenicity of the remainder of the liver is appreciated, then the area of normal hepatic parenchyma may be helpful in making the diagnosis of fatty change[38].

Several studies have assessed the sensitivity and specificity of ultrasound for detecting hepatic steatosis. In these, the sensitivity ranged from 60% to 94% and the specificity from 84% to 95%, respectively[35,39-41]. Another study combined fatty change with fibrosis and obtained a sensitivity of 98.7% and specificity of 94% for the "fatty fibrotic pattern"[42]. The sensitivity of ultrasound increases with increasing degrees of fatty infiltration. For example, in the presence of hepatic fat content of 10% to 19%, it has a sensitivity of 55%, which rises to 80% in the presence of > 30% fatty infiltration[43]. However, in the presence of morbid obesity (defined by a body mass index > 40 kg/m²), the sensitivity and specificity of ultrasound fall to 49% and 75%, respectively, possibly due to technical problems in performing ultrasound in such patients[44].

Whereas ultrasound is a useful technique for detecting hepatic steatosis, particularly in severe cases, it is unable to provide a precise determination of hepatic fat content. Grading of hepatic fat content into broad categories (mild, moderate and severe steatosis) has been reported, using diagnostic criteria, based upon the visual assessment of hepatic echogenicity[35,41,42,45,46]. However, all of the above studies found the grading of hepatic fat content using ultrasound to be somewhat subjective. In addition, the most recent ones showed that ultrasound is very poor at discriminating small changes in hepatic fat content. For example, Fishbein and colleagues suggested from their study that an individual with hepatic steatosis undergoing a reduction of MRI hepatic fat fraction from 40% to 20% through successful intervention, would be unlikely to have a corresponding alteration in ultrasound appearance[45].

The operator dependency of ultrasound, its inability to precisely quantify hepatic fat content, and its inability to detect small changes in liver fat with time, all potentially limit its use in longitudinal clinical studies.

Computerized tomography
Contrast-unenhanced Computerized tomography (CT) is the most accurate CT technique used to detect and characterise hepatic steatosis[47]. The CT diagnosis of hepatic steatosis is made by measuring the difference in liver and spleen attenuation values in Hounsfield units[48]. In individuals without hepatic steatosis, the mean attenuation value for the liver is at least 4 Hounsfield units greater than for the spleen[48]. However, in subjects with hepatic steatosis, the mean attenuation value for the liver is lower than that for the spleen, so the liver appears darker than the spleen, rather than brighter. This lower attenuation of the liver in hepatic steatosis is thought to be secondary to the accumulation of lipids (triglycerides and cholesterol) within the hepatocytes[49]. With severe hepatic steatosis, there is more marked contrast between the liver and intrahepatic vessels. The increased brightness of the vessels relative to the liver parenchyma may erroneously suggest the use of contrast (Figure 2)[36].

Great care should be taken in diagnosing fatty infiltration of the liver on contrast-enhanced CT scans because contrast injection rate and timing of measurements can significantly influence the optimal liver-minus-spleen attenuation difference for diagnosing fatty liver[50,51]. It has been suggested that muscle, rather than spleen, may be a better qualitative standard of reference for diagnosing fatty liver on contrast-enhanced CT, and that fatty liver can be diagnosed if the liver has a lower attenuation value than muscle[52]. However, such a comparison works only if the degree of fatty infiltration is severe.

Although non-contrast-enhanced CT is very good for the qualitative diagnosis of macrovesicular steatosis of 30% or greater, there is conflicting evidence to as to whether or not it can accurately quantify hepatic fat content. Some studies have demonstrated that

Figure 3 Principles of magnetic resonance. The magnetic resonance (MR) signal or free induction decay (FID) may be converted by the mathematical process of Fourier transformation to form anatomical information (MR imaging) or localised biochemical information (MR spectroscopy). Modified from Taylor-Robinson SD Applications of magnetic resonance spectroscopy to chronic liver disease. *Clin Med* 2001; 1: 54-60 Copyright © 2001 Royal College of Physicians. *Adapted by permission*.

both the CT numbers for the liver and the ratio of CT numbers for the liver and the spleen show a good inverse correlation with the degree of steatosis seen on liver biopsy[47,53,54]. Nevertheless, it should be noted that a more recent study by Park and colleagues concluded that the diagnostic performance of unenhanced CT for quantitative assessment of macrovesicular steatosis is not clinically acceptable[55]. In addition, CT scanning has the drawback of exposing subjects to ionizing radiation. The above two factors limit its potential use in longitudinal studies and in children.

Magnetic resonance imaging and proton magnetic resonance spectroscopy

Principles of magnetic resonance imaging and spectroscopy: The nuclear magnetic resonance (NMR) phenomenon was first reported by Bloch *et al* in 1946[56]. NMR techniques exploit the behaviour of certain atomic nuclei in an externally applied magnetic field. Magnetic resonance sensitive nuclei, such as hydrogen-1 (^{1}H), carbon-13 (^{13}C), nitrogen-15 (^{15}N) and phosphorous-31 (^{31}P) possess the quantum mechanical property of "spin", a source of angular momentum intrinsic to nuclei with an odd mass number. When placed in a magnetic field they behave like magnetic dipoles, aligning parallel to or against the axis of the applied static magnetic field. When excited by irradiation with non-ionizing radiofrequency (rf) energy, this alignment of the nuclei is disturbed. During relaxation following excitation, the nuclei return to their original orientation, giving off a radiofrequency signal, which may then be detected by a receiver coil. This signal, known as the free induction decay (FID), can be resolved by a computer-based mathematical process known as Fourier transformation into either an image, providing anatomical information (MRI) or a frequency spectrum, providing biochemical information (MRS)[57,58], as shown in Figure 3.


Figure 4 In and opposed phase MR images of a liver illustrating the signal drop-off from an in-phase (**A**) to an opposed-phase image (**B**) in a patient with marked steatosis. Reproduced from Rinella *et al*. *Liver Transplantation* 2003; 9: 851-856. Copyright (2003) American Association for the Study of Liver Diseases. Reprinted with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.

MAGNETIC RESONANCE IMAGING

Nuclei from individual metabolites resonate at a given, but unique frequency, depending on the molecular structure of each compound. This is known as chemical shift and occurs because nuclei in different chemical environments experience slightly different magnetic field strengths. This variation in magnetic field strength results from the intrinsic "shielding" offered by the nearby electrons, which partially counteract the force of the main magnetic field. For example, the hydrogen nuclei in water (O-H bond) have less surrounding electrons than the hydrogen nuclei in lipid (C-H bond), so experience a slightly stronger magnetic field and, as a result, rotate at a slightly higher resonance frequency. The differences are extremely small and are typically measured using the dimensionless unit, parts per million (ppm)[59].

Chemical shift MR imaging utilises this difference in resonance frequency of water and lipid to differentiate tissues containing only water from those containing both water and lipid[60], as illustrated in Figure 4.

Applying this principle, Dixon developed a modified spin echo technique, now widely known as the Dixon method[61]. Using this technique, Lee and co-workers scanned the livers of five humans, two healthy volunteers with no evidence of liver disease and three patients with CT evidence of fatty infiltration of the liver[62]. In the subjects with CT evidence of hepatic fatty infiltration, there was a notable loss of signal

Figure 5 Proton magnetic resonance spectra from three volunteers showing progressive degrees of hepatic fatty infiltration. Resonances from water and lipid (IHCL CH2) can be clearly seen. For each individual hepatic fatty infiltration was quantified using the equation: -Percentage fat = IHCL CH2 peak area/Water peak area × 100. Shown are spectra from a liver with very mild fatty infiltration (1.0%), a liver with moderate fatty infiltration (10.2%), and a liver with severe fatty infiltration (74.9%). Adapted from Thomas *et al. Gut* 2005; 54: 122-127, with permission from the BMJ Publishing Group.

intensity on the out-of-phase images (because opposing signals from water and lipid tended to cancel each other out), and a less appreciable increase in signal intensity on the in-phase images. In contrast, in the healthy volunteers without hepatic steatosis, the signal intensity of the liver parenchyma was not altered between in-phase and out-of-phase images. They concluded that the Dixon method was capable of distinguishing fatty liver from normal liver, and that it might also be useful for the quantification of liver fat. Using the same technique, Heiken and colleagues scanned the livers of 35 subjects (12 healthy volunteers and 23 patients with CT evidence of fatty infiltration of the liver)[63]. They demonstrated the Dixon method to be a clinically useful technique for detecting and quantifying fatty infiltration of the liver and for differentiating non-uniform fatty infiltration from liver metastases[63]. However, this methodology has its limitations. It was time-consuming, and the quality of the images obtained was affected by respiratory and other motion artefacts, as well as by magnetic field inhomogeneities[61,64].

Since these early studies, many researchers have developed modifications of the Dixon method with the aim to reduce these limitations. Levenson and colleagues used the technique to quantify hepatic fat in 16 subjects with a variety of liver abnormalities, and compared the imaging results with those from liver biopsies[65]. The results were reproducible and there was reasonably good correlation between the imaging and biopsy findings[65]. In pursuit of a quick, accurate, non-invasive evaluation of hepatic steatosis, Fishbein and co-workers developed a fast gradient echo technique, which allowed them to obtain images of the liver in both adults and children, using breath holding manoeuvres[66]. This technique not only reduced the time taken for the scan, but had the advantage of reducing motion artefact due to respiration. Using the same scanning sequence, these authors compared hepatic MRI with ultrasound and liver biopsy in quantifying hepatic fat in 38 patients with a variety of liver diseases[45]. Both MRI and ultrasound assessment of steatosis severity correlated well with liver histology, but MRI was superior to ultrasound in detecting and quantifying minor degrees of hepatic steatosis. Several other groups have also demonstrated a good correlation between the severity of hepatic steatosis on MRI and liver biopsy[67-69]. Recently, Qayyum and colleagues studied 27 patients, 16 with cirrhosis, and compared two different MRI techniques in quantifying hepatic fat. Their preliminary results suggested that liver fat may be more accurately quantified with fat-saturated fast spin-echo MR imaging than with out-of-phase gradient echo MR imaging, especially in patients with cirrhosis[70].

Further modifications continue to be made to the Dixon method for water and fat separation, such as the recently reported fast spin-echo triple-echo Dixon (fTED) technique, which enables both uniform water/fat separation and fast scanning with uncompromised scan parameters[71]. Thus, in the future, chemical shift MRI is likely to provide an accurate, safe and fast method of detecting and quantifying hepatic steatosis in both adults and children.

PROTON MAGNETIC RESONANCE SPECTROSCOPY

Chemical shift magnetic resonance imaging enables the identification of tissues that contain a significant proportion of intracellular lipid. In contrast, proton magnetic resonance spectroscopy (^{1}H MRS) facilitates the examination of the resonance frequencies of all hydrogen nuclei (protons) within a region of interest. Although the absolute differences in resonance frequencies in MRS are quite small, they can be separated out to form a spectrum. Frequency separation, and hence spectral resolution, is determined by the strength of the main magnetic field. The MR spectra are plotted on an axis of chemical shift. With MR spectroscopy, the concentration of any given molecule in a sample is represented by the area under the specific resonance peak within the spectrum. Quantification of hepatic fat using proton MR spectroscopy requires evaluation of the two dominant peaks within the unsuppressed MR spectrum, water at 4.7 ppm and lipid at 1.0-1.5 ppm[59]. Livers with fatty infiltration demonstrate an increase in the intensity of the lipid resonance peak as shown in Figure 5.

Since proton magnetic resonance spectroscopy allows direct measurement of the area under the lipid resonance, it can be used to provide a quantitative assessment of fatty infiltration of the liver. Allowance must be made for both T_1 and T_2 relaxation effects, which differ for lipid and water. A correction must also be made for unsaturated lipids, as a portion of the MR

signal from these molecules overlaps with the water resonance at 4.7 ppm[59].

Allowing for these corrections, Longo and colleagues studied a population of subjects with non-alcoholic fatty liver disease and found the percentage hepatic lipid measurements using ^{1}H MRS correlated well with those obtained by CT and liver biopsy[54,72]. Thomsen and co-workers demonstrated similar results in patients with alcohol-induced fatty liver disease[73]. Since then, several other studies have shown ^{1}H MRS to be a fast, safe, non-invasive method for the quantification of hepatic fat content[74-78]. Recently, ^{1}H MRS has been used in a large United States population study to determine the prevalence of non-alcoholic fatty liver disease in the general adult population[79] and also in longitudinal clinical studies[80-84]. However, in most centres ^{1}H MRS remains largely a research tool, despite the fact that all commercially available MR scanners have MRS capabilities.

CONCLUSION

Non-alcoholic fatty liver disease (NAFLD) is now recognized as the most common cause of chronic liver disease in the Western World[31]. Its prevalence will likely increase in the future in parallel with the predicted increase in obesity and Type 2 diabetes. Currently, the only proven treatments for this condition are lifestyle measures, such as dietary modification and exercise[82,85-87].

Liver biopsy remains the gold standard investigation for determining hepatic fat deposition, but it is an invasive procedure and may be prone to sampling error.

Of the non-invasive imaging techniques used to detect fatty infiltration of the liver, ultrasound is the most widely used in clinical practice today. It will remain popular in the future due to its widespread availability and excellent tolerability. Magnetic resonance techniques using chemical shift imaging and *in vivo* ^{1}H MRS have an advantage over ultrasound in that they are able to detect small changes in liver fat content. They can be performed as an adjunct to whole body MRI, as part of the same examination, allowing a comparison to be made between hepatic fat content and whole body adipose tissue distribution in the same subject. Thus, in the future, as more technological advances are made and scanning times shorten further, it is anticipated that both techniques will be used much more widely, both in longitudinal clinical research studies, but also in clinical practice.

ACKNOWLEDGMENTS

REFERENCES

1   **Sanyal AJ**. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. *Nat Clin Pract Gastroenterol Hepatol* 2005; **2**: 46-53

2   **Kershaw EE**, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 2004; **89**: 2548-2556

3   **Scherer PE**. Adipose tissue: from lipid storage compartment to endocrine organ. *Diabetes* 2006; **55**: 1537-1545

4   **Yang Q**, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 2005; **436**: 356-362

5   **Zhang Y**, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994; **372**: 425-432

6   **Scherer PE**, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem* 1995; **270**: 26746-26749

7   **Steppan CM**, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. *Nature* 2001; **409**: 307-312

8   **Fukuhara A**, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* 2005; **307**: 426-430

9   **Unger RH**. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. *Endocrinology* 2003; **144**: 5159-5165

10 **Montani JP**, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. *Int J Obes Relat Metab Disord* 2004; **28** Suppl 4: S58-S65

11 **Capeau J**, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C, Bastard JP. Diseases of adipose tissue: genetic and acquired lipodystrophies. *Biochem Soc Trans* 2005; **33**: 1073-1077

12 **Monajemi H**, Stroes E, Hegele RA, Fliers E. Inherited lipodystrophies and the metabolic syndrome. *Clin Endocrinol (Oxf)* 2007; **67**: 479-484

13 **Simha V**, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. *Curr Opin Lipidol* 2006; **17**: 162-169

14 **Bloomgarden ZT**. Gut hormones, obesity, polycystic ovarian syndrome, malignancy, and lipodystrophy syndromes. *Diabetes Care* 2007; **30**: 1934-1939

15 **Payne JH**, Dewind LT, Commons RR. Metabolic Observations in Patients with Jejunocolic Shunts. *Am J Surg* 1963; **106**: 273-289

16 **McGill DB**, Humpherys SR, Baggenstoss AH, Dickson ER. Cirrhosis and death after jejunoileal shunt. *Gastroenterology* 1972; **63**: 872-877

17 **Catlin R**. Liver dysfunction after intestinal bypass. *JAMA* 1976; **236**: 1693-1694

18 **Peters RL**, Gay T, Reynolds TB. Post-jejunoileal-bypass hepatic disease. Its similarity to alcoholic hepatic disease. *Am J Clin Pathol* 1975; **63**: 318-331

19 **Thaler H**. Relation of steatosis to cirrhosis. *Clin Gastroenterol* 1975; **4**: 273-280

20 **Adler M**, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. *Am J Med* 1979; **67**: 811-816

21 **Nasrallah SM**, Wills CE Jr, Galambos JT. Hepatic morphology in obesity. *Dig Dis Sci* 1981; **26**: 325-327

22 **Itoh S**, Tsukada Y, Motomura Y, Ichinoe A. Five patients with nonalcoholic diabetic cirrhosis. *Acta Hepatogastroenterol*

(Stuttg) 1979; **26**: 90-97

23   **Falchuk KR**, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. *Gastroenterology* 1980; **78**: 535-541

24   **Hornboll P**, Olsen TS. Fatty changes in the liver: the relation to age, overweight and diabetes mellitus. *Acta Pathol Microbiol Immunol Scand* [A] 1982; **90**: 199-205

25   **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438

26   **Powell EE**, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology* 1990; **11**: 74-80

27   **Matteoni CA**, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999; **116**: 1413-1419

28   **Dam-Larsen S**, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004; **53**: 750-755

29   **Teli MR**, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995; **22**: 1714-1719

30   **Angulo P**. Nonalcoholic fatty liver disease. *N Engl J Med* 2002; **346**: 1221-1231

31   **Adams LA**, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. *CMAJ* 2005; **172**: 899-905

32   **Crowley H**, Lewis WD, Gordon F, Jenkins R, Khettry U. Steatosis in donor and transplant liver biopsies. *Hum Pathol* 2000; **31**: 1209-1213

33   **Joseph AE**, Dewbury KC, McGuire PG. Ultrasound in the detection of chronic liver disease (the "bright liver"). *Br J Radiol* 1979; **52**: 184-188

34   **Quinn SF**, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. *AJR Am J Roentgenol* 1985; **145**: 753-755

35   **Joseph AE**, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol* 1991; **43**: 26-31

36   **Joy D**, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? *Eur J Gastroenterol Hepatol* 2003; **15**: 539-543

37   **Kissin CM**, Bellamy EA, Cosgrove DO, Slack N, Husband JE. Focal sparing in fatty infiltration of the liver. *Br J Radiol* 1986; **59**: 25-28

38   **Caturelli E**, Squillante MM, Andriulli A, Cedrone A, Cellerino C, Pompili M, Manoja ER, Rapaccini GL. Hypoechoic lesions in the 'bright liver': a reliable indicator of fatty change. A prospective study. *J Gastroenterol Hepatol* 1992; **7**: 469-472

39   **Foster KJ**, Dewbury KC, Griffith AH, Wright R. The accuracy of ultrasound in the detection of fatty infiltration of the liver. *Br J Radiol* 1980; **53**: 440-442

40   **Debongnie JC**, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. *Gut* 1981; **22**: 130-135

41   **Saverymuttu SH**, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. *Br Med J* (Clin Res Ed) 1986; **292**: 13-15

42   **Needleman L**, Kurtz AB, Rifkin MD, Cooper HS, Pasto ME, Goldberg BB. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. *AJR Am J Roentgenol* 1986; **146**: 1011-1015

43   **Ryan CK**, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. *Liver Transpl* 2002; **8**: 1114-1122

44   **Mottin CC**, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G. The role of ultrasound in

the diagnosis of hepatic steatosis in morbidly obese patients. *Obes Surg* 2004; **14**: 635-637

45   **Fishbein M**, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. *J Clin Gastroenterol* 2005; **39**: 619-625

46   **Pacifico L**, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. *Acta Paediatr* 2007; **96**: 542-547

47   **Bydder GM**, Kreel L, Chapman RW, Harry D, Sherlock S, Bassan L. Accuracy of computed tomography in diagnosis of fatty liver. *Br Med J* 1980; **281**: 1042

48   **Piekarski J**, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. *Radiology* 1980; **137**: 727-729

49   **Kawata R**, Sakata K, Kunieda T, Saji S, Doi H, Nozawa Y. Quantitative evaluation of fatty liver by computed tomography in rabbits. *AJR Am J Roentgenol* 1984; **142**: 741-746

50   **Johnston RJ**, Stamm ER, Lewin JM, Hendrick RE, Archer PG. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. *Abdom Imaging* 1998; **23**: 409-415

51   **Jacobs JE**, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. *AJR Am J Roentgenol* 1998; **171**: 659-664

52   **Panicek DM**, Giess CS, Schwartz LH. Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen? *J Comput Assist Tomogr* 1997; **21**: 699-705

53   **Pamilo M**, Sotaniemi EA, Suramo I, Lahde S, Arranto AJ. Evaluation of liver steatotic and fibrous content by computerized tomography and ultrasound. *Scand J Gastroenterol* 1983; **18**: 743-747

54   **Longo R**, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L, Tiribelli C, Dalla Palma L. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. *Invest Radiol* 1993; **28**: 297-302

55   **Park SH**, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, Ha HK, Lee MG, Hwang S, Lee SG, Yu ES, Cho EY. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. *Radiology* 2006; **239**: 105-112

56   **Bloch F**, Hansen WW, Packard ME. Nuclear induction. *Phys Rev* 1946; **69**: 127

57   **Cox IJ**. Development and applications of in vivo clinical magnetic resonance spectroscopy. *Prog Biophys Mol Biol* 1996; **65**: 45-81

58   **Taylor-Robinson SD**. Applications of magnetic resonance spectroscopy to chronic liver disease. *Clin Med* 2001; **1**: 54-60

59   **Siegelman ES**, Rosen MA. Imaging of hepatic steatosis. *Semin Liver Dis* 2001; **21**: 71-80

60   **Venkataraman S**, Braga L, Semelka RC. Imaging the fatty liver. *Magn Reson Imaging Clin N Am* 2002; **10**: 93-103

61   **Dixon WT**. Simple proton spectroscopic imaging. *Radiology* 1984; **153**: 189-194

62   **Lee JK**, Dixon WT, Ling D, Levitt RG, Murphy WA Jr. Fatty infiltration of the liver: demonstration by proton spectroscopic imaging. Preliminary observations. *Radiology* 1984; **153**: 195-201

63   **Heiken JP**, Lee JK, Dixon WT. Fatty infiltration of the liver: evaluation by proton spectroscopic imaging. *Radiology* 1985; **157**: 707-710

64   **Outwater EK**, Blasbalg R, Siegelman ES, Vala M. Detection of lipid in abdominal tissues with opposed-phase gradient-echo images at 1.5 T: techniques and diagnostic importance. *Radiographics* 1998; **18**: 1465-1480

65 **Levenson H**, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, Kanel G, Buxton R. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. *AJR Am J Roentgenol* 1991; **156**: 307-312

66 **Fishbein MH**, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. *Magn Reson Imaging* 1997; **15**: 287-293

67 **Rinella ME**, McCarthy R, Thakrar K, Finn JP, Rao SM, Koffron AJ, Abecassis M, Blei AT. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. *Liver Transpl* 2003; **9**: 851-856

68 **Hussain HK**, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, Appelman HD, Adusumilli S, Greenson JK, Conjeevaram HS. Hepatic fat fraction: MR imaging for quantitative measurement and display-early experience. *Radiology* 2005; **237**: 1048-1055

69 **Pilleul F**, Chave G, Dumortier J, Scoazec JY, Valette PJ. Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. *Gastroenterol Clin Biol* 2005; **29**: 1143-1147

70 **Qayyum A**, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. *Radiology* 2005; **237**: 507-511

71 **Ma J**, Son JB, Zhou Y, Le-Petross H, Choi H. Fast spin-echo triple-echo dixon (fTED) technique for efficient T2-weighted water and fat imaging. *Magn Reson Med* 2007; **58**: 103-109

72 **Longo R**, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. *J Magn Reson Imaging* 1995; **5**: 281-285

73 **Thomsen C**, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. *Magn Reson Imaging* 1994; **12**: 487-495

74 **Thomas EL**, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectros-copy study. *Gut* 2005; **54**: 122-127

75 **Szczepaniak LS**, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. *Am J Physiol* 1999; **276**: E977-E989

76 **Kotronen A**, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. *J Clin Endocrinol Metab* 2007; **92**: 3490-3497

77 **Seppala-Lindroos A**, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J Clin Endocrinol Metab* 2002; **87**: 3023-3028

78 **Ostberg JE**, Thomas EL, Hamilton G, Attar MJ, Bell JD, Conway GS. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. *J Clin Endocrinol Metab* 2005; **90**: 2631-2635

79 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395

80 **Westerbacka J**, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, Yki-Jarvinen H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. *J Clin Endocrinol Metab* 2005; **90**: 2804-2809

81 **Tiikkainen M**, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. *Diabetes* 2004; **53**: 2169-2176

82 **Thomas EL**, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, Frost G, Bell JD, Taylor-Robinson SD. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. *World J Gastroenterol* 2006; **12**: 5813-5819

83 **Belfort R**, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; **355**: 2297-2307

84 **Thomas EL**, Potter E, Tosi I, Fitzpatrick J, Hamilton G, Amber V, Hughes R, North C, Holvoet P, Seed M, Betteridge DJ, Bell JD, Naoumova RP. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. *Atherosclerosis* 2007; **195**: e181-e190

85 **Park HS**, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. *J Korean Med Sci* 1995; **10**: 414-421

86 **Ueno T**, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol* 1997; **27**: 103-107

87 **Zelber-Sagi S**, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2006; **4**: 639-644